TETRAVECTA Trademark

Trademark Overview


On Monday, March 4, 2024, a trademark application was filed for TETRAVECTA with the United States Patent and Trademark Office. The USPTO has given the TETRAVECTA trademark a serial number of 98432248. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Tuesday, January 21, 2025. This trademark is owned by Oxford BioMedica Plc. The TETRAVECTA trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of products relating to biotechnology, namely, custom manufacture of cell and gene therapies; custom manufacture of gene and cell-based therapy products, namely, cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of cell and gene therapies, and biopharmaceutical preparations; biotechnology contract manufacturing services, namely, contract manufacturing in the field of cell and gene therapy using biological organisms; contract manufacturing services of gene and cell-based therapy products, namely, cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vec...

Research and laboratory analytic and diagnostic services, namely, scientific research, biochemical research, research laboratory analysis services in the field of gene therapy and biochemistry; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector product and analytic assay product development for others; laboratory services, namely, scientific laboratory services and biological research laboratory services; research and development services, namely, gene therapy research; genetic engineering laboratories, namely, scientific research in the field of genetic engineering provided in genetic engineering laboratories and biochemistry laboratories providing research and development in the field of biochemistry; scientific and technological services and research, namely, scientific research, analysis, testing in the fields of gene therapy and biochemistry; industrial analysis services, namely, providing analysis ...
tetravecta

General Information


Serial Number98432248
Word MarkTETRAVECTA
Filing DateMonday, March 4, 2024
Status653 - SUSPENSION LETTER - MAILED
Status DateTuesday, January 21, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCustom manufacture of products relating to biotechnology, namely, custom manufacture of cell and gene therapies; custom manufacture of gene and cell-based therapy products, namely, cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of cell and gene therapies, and biopharmaceutical preparations; biotechnology contract manufacturing services, namely, contract manufacturing in the field of cell and gene therapy using biological organisms; contract manufacturing services of gene and cell-based therapy products, namely, cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of cell and gene therapies and biopharmaceutical products, namely, cell and gene therapies; contract manufacturing services of technology for biopharmaceutical products and gene and cell-based products, namely, custom manufacture of cell and gene therapies; contract manufacturing services of technology for viral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, adenoviral vectors, and non-vector preparations, namely, custom manufacture of cell and gene therapies
Goods and ServicesResearch and laboratory analytic and diagnostic services, namely, scientific research, biochemical research, research laboratory analysis services in the field of gene therapy and biochemistry; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector product and analytic assay product development for others; laboratory services, namely, scientific laboratory services and biological research laboratory services; research and development services, namely, gene therapy research; genetic engineering laboratories, namely, scientific research in the field of genetic engineering provided in genetic engineering laboratories and biochemistry laboratories providing research and development in the field of biochemistry; scientific and technological services and research, namely, scientific research, analysis, testing in the fields of gene therapy and biochemistry; industrial analysis services, namely, providing analysis services with respect to gene-therapy based product manufacturing for industrial purposes; provision of information relating to scientific research; provision of scientific information in the fields of gene therapy and biochemistry; product research and scientific analysis of cell and gene therapies relating to drug discovery and product development for others; scientific advisory services relating to biochemistry; scientific consultancy services relating to biochemistry; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, March 4, 2024
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, March 4, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOxford BioMedica Plc
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressOxford OX46LT
GB

Trademark Events


Event DateEvent Description
Monday, March 4, 2024NEW APPLICATION ENTERED
Monday, July 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, September 25, 2024NON-FINAL ACTION WRITTEN
Wednesday, September 25, 2024NON-FINAL ACTION E-MAILED
Monday, December 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 21, 2025LETTER OF SUSPENSION E-MAILED
Tuesday, January 21, 2025SUSPENSION LETTER WRITTEN
Tuesday, January 21, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, September 18, 2024ASSIGNED TO EXAMINER
Tuesday, December 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED